Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Clover Health Investments, Corp. insider Conrad Wai, CEO of Counterpart Health, reported a routine tax-related share withholding. On March 14, 2026, 100,195 shares of Class A Common Stock were automatically withheld to cover tax obligations when the final 6.25% of his time-based RSUs granted on March 14, 2022 vested.
Following this tax-withholding disposition, Wai directly holds 925,611 shares of Class A Common Stock. He also has an indirect position of 1,610,482 shares held in a trust for his family's benefit, where he serves as co-trustee. The filing reflects compensation-related mechanics rather than an open-market sale.
Clover Health Investments, Corp. filed an amended report furnishing a supplemental shareholder Q&A that expands on its fourth quarter 2025 earnings communication. Management emphasizes that its 2026 guidance is anchored on achieving positive full-year GAAP net income, positioning this as proof of structural earnings power in its Medicare Advantage model.
The Q&A explains that strong member retention, a 4-Star payment year in 2026, cohort maturation, and deeper use of the Clover Assistant technology are expected to support improving unit economics. Clover describes its approach as focused on disciplined underwriting, operating leverage and medical cost performance rather than relying on favorable reimbursement changes.
The company also discusses pausing most broker commissions from January 1, 2026 outside selected New Jersey plans to prioritize onboarding quality and provider integration, outlines a strategy to improve Star Ratings, and highlights Counterpart Health as an asset-light, technology-driven platform built on Clover Assistant to help external partners manage risk and care more effectively over time.
Clover Health Investments, Corp. furnished an update to investors by publishing written responses to a selection of frequently asked supplemental questions related to its fourth quarter 2025 earnings announcement. The company aims to further engage its shareholder base through this additional Q&A material.
The supplemental shareholder questions and answers are included as Exhibit 99.1 to this report and are also available in the investor relations section of the company’s website. This information is furnished under Regulation FD and is not deemed filed for liability purposes under the Exchange Act.
Clover Health Investments executive Brady Patrick Priest, CEO of Home Care, reported an open-market sale of Class A Common Stock. On March 4, 2026, he sold 175,000 shares at a weighted average price of $2.17 per share, in multiple trades between $2.16 and $2.18.
After this transaction, Priest held 1,998,584 shares of Clover Health Class A Common Stock in direct ownership.
CLOV reported a proposed sale of 175000 common shares under a Form 144. The filing lists a broker-dealer Morgan Stanley Smith Barney LLC Executive Financial Services and shows transaction details dated 03/04/2026.
The filing also itemizes restricted stock lots with grant/vesting dates: 57,627 (10/18/2025), 69,009 (01/18/2026) and 48,364 (10/15/2025).
Clover Health Investments, Corp. files its annual report describing a technology-focused Medicare Advantage business that remains unprofitable while pursuing growth. The company reported net losses of $85.5 million in 2025, $46.3 million in 2024, and $210.1 million in 2023, resulting in an accumulated deficit of roughly $2.3 billion as of December 31 2025.
Clover’s strategy centers on its Clover Assistant software, which uses data and machine learning to support physicians in managing chronic disease earlier and lowering medical costs. The platform underpins its Medicare Advantage plans and a newer external SaaS and tech-enabled services offering, Counterpart Health, aimed at other payors and providers.
The report highlights heavy dependence on Medicare Advantage premiums, intense competition from large insurers and health-tech players, and extensive regulatory oversight. Management flags risks from ongoing net losses, potential capital needs, cybersecurity and privacy requirements, government payment and audit processes, and the concentration of voting power in Class B shareholders.
Clover Health Investments reported strong growth for 2025 but remained unprofitable on a GAAP basis while turning profitable on key non-GAAP metrics and setting targets for 2026 profitability. Full-year 2025 Medicare Advantage membership reached 113,803, up 38%, and total revenues were $1.9 billion, up 40% year-over-year. The company recorded a 2025 GAAP net loss of $86 million, but delivered $22 million of Adjusted EBITDA and $20 million of Adjusted Net Income from continuing operations, indicating an improved underlying earnings profile despite reported losses. Cash, cash equivalents, and investments totaled $319.9 million at year-end, down from $437.6 million a year earlier.
For full-year 2026, Clover Health guides to total revenues between $2.81 billion and $2.92 billion, consolidated gross profit of $470–$510 million, Adjusted EBITDA of $50–$70 million, and GAAP net income between $0 and $20 million, which would mark its first full year of GAAP profitability. Average Medicare Advantage membership is expected to rise to 154,000–158,000, about 46% growth at the midpoint, as the company leans on its Clover Assistant technology and wide-network PPO strategy.
Clover Health Investments General Counsel & Secretary Karen Soares reported a tax-related share disposition. On February 14, 2026, 6,090 shares of Class A common stock were automatically withheld at $2.02 per share to cover tax obligations upon vesting of restricted stock units granted on February 14, 2022. After this withholding, she directly owned 1,204,589 Class A shares.
Clover Health Investments’ Chief Executive Officer and director Andrew Toy reported an automatic share withholding tied to restricted stock unit (RSU) vesting. On February 8, 2026, 85,704 shares of Class A common stock were withheld at $2.13 per share to cover tax obligations arising from the vesting of 6.25% of his original time-based RSU grant from August 8, 2022. After this tax withholding, Toy beneficially owned 9,423,021 shares of Class A common stock directly. The remaining RSUs from the 2022 grant are scheduled to vest quarterly in equal 6.25% installments through August 8, 2026, subject to his continued service.
Clover Health Investments Chief Financial Officer Peter J. Kuipers reported a routine tax-related share withholding. On January 29, 2026, 156,856 shares of Class A Common Stock were automatically withheld at $2.31 per share to cover tax obligations from vesting restricted stock units.
This withholding relates to 6.25% of the original time-based RSU grant awarded on April 29, 2024. After the transaction, Kuipers beneficially owned 5,758,353 Class A shares. The remaining RSUs are scheduled to vest in equal quarterly installments through April 29, 2028, subject to his continued service.